Provided herein is a compound of Formula (I-I) or a pharmaceutically acceptable salt thereof, wherein t, R.sup.7, R.sup.3, R.sup.9, R.sup.6a, R.sup.6b, R.sup.11a, R.sup.11b, R.sup.15a, R.sup.15b, R.sup.16a, R.sup.16b, R.sup.17a, R.sup.17b, R.sup.18a, R.sup.18b, R.sup.19a, R.sup.19b, R.sup.5a, R.sup.5b, R.sup.8 and R.sup.13 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I-I) and methods of using the compounds, e.g., in the treatment of CNS-related disorders.

##STR00001##

Disclosed herein are novel sialyltransferase inhibitors, and compositions and methods for treating diseases and/or conditions associated with the activation of sialyltransferase, such as a cancer, an immune disease or an inflammatory disease.

Disclosed herein are novel sialyltransferase inhibitors, and compositions and methods for treating diseases and/or conditions associated with the activation of sialyltransferase, such as a cancer, an immune disease or an inflammatory disease.

Provided herein is a compound of Formula (I-I) or a pharmaceutically acceptable salt thereof, wherein t, R.sup.7, R.sup.3, R.sup.9, R.sup.6a, R.sup.6b, R.sup.11a, R.sup.11b, R.sup.15a, R.sup.15b, R.sup.16a, R.sup.16b, R.sup.17a, R.sup.17b, R.sup.18a, R.sup.18b, R.sup.19a, R.sup.19b, R.sup.5a, R.sup.5b, R.sup.8 and R.sup.13 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I-I) and methods of using the compounds, e.g., in the treatment of CNS-related disorders.

##STR00001##